Self-Injections Global Market Opportunities and Strategies to 2033

This report describes and explains the self-injections market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global self-injections market reached a value of nearly $9.3 billion in 2023, having grown at a compound annual growth rate (CAGR) of 6.7% since 2018. The market is expected to grow from $9.3 billion in 2023 to $13.2 billion in 2028 at a rate of 7.2%. The market is then expected to grow at a CAGR of 7.9% from 2028 and reach $19.2 billion in 2033.

Growth in the historic period resulted from the patient preference for home care services, shift towards personalized medicine and rise in telehealth and telemedicine. Factors that negatively affected growth in the historic period was lack of patient education and training.

Going forward, rise in chronic diseases, rising healthcare expenditure, increase in the aging population and strong economic growth will drive the growth. Factors that could hinder the growth of the self-injections market in the future include regulatory hurdles and needle phobia and anxiety.

The self-injections market is segmented by type into devices and formulations. The devices market was the largest segment of the self-injections market segmented by type, accounting for 65.7% or $6.1 billion of the total in 2023. Going forward, the formulations segment is expected to be the fastest growing segment in the self-injections market segmented by type, at a CAGR of 7.8% during 2023-2028.

The self-injections market is segmented by application into cancer, autoimmune diseases, hormonal disorders, pain management and other applications. The hormonal disorders market was the largest segment of the self-injections market segmented by application, accounting for 39.3% or $3.7 billion of the total in 2023. Going forward, the pain management segment is expected to be the fastest growing segment in the self-injections market segmented by application, at a CAGR of 8.7% during 2023-2028.

The self-injections market is segmented by route of administration into skin, circulatory or musculoskeletal, organs and central nervous system. The skin market was the largest segment of the self-injections market segmented by route of administration, accounting for 64.1% or $6 billion of the total in 2023. Going forward, the skin segment is expected to be the fastest growing segment in the self-injections market segmented by route of administration, at a CAGR of 7.4% during 2023-2028.

The self-injections market is segmented by distribution channel into hospital pharmacies, clinics, chemists and online pharmacies. The hospital pharmacies market was the largest segment of the self-injections market segmented by distribution channel, accounting for 41.5% or $3.9 billion of the total in 2023. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the self-injections market segmented by distribution channel, at a CAGR of 9.9% during 2023-2028.

The self-injections market is segmented by dosage into single dose and multi dose. The single dose market was the largest segment of the self-injections market segmented by dosage, accounting for 63.5% or $5.9 billion of the total in 2023. Going forward, the multi dose segment is expected to be the fastest growing segment in the self-injections market segmented by dosage, at a CAGR of 7.7% during 2023-2028.

North America was the largest region in the self-injections market, accounting for 34.5% or $3.21 billion of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the self-injections market will be Asia Pacific and North America where growth will be at CAGRs of 8.2% and 7.5% respectively. These will be followed by Western Europe and South America where the markets are expected to grow at CAGRs of 7% and 5.6% respectively.

The global self-injections market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 33% of the total market in 2022. Pfizer Inc. was the largest competitor with an 8% share of the market, followed by Becton Dickinson and Company with 5.3%, Ypsomed Holding AG with 5.1%, Eli Lilly and Company with 4.1%, Merck & Co. Inc. with 3%, Bristol-Myers Squibb Company with 1.9%, Insulet Corporation with 1.8%, Bayer AG with 1.7%, Halozyme Therapeutics, Inc. with 1.1% and Abbvie Inc with 1%.

The top opportunities in the self-injections market segmented by type will arise in the devices segment, which will gain $2.4 billion of global annual sales by 2028. The top opportunities in the self-injections market segmented by application will arise in the hormonal disorders segment, which will gain $1.4 billion of global annual sales by 2028. The top opportunities in the self-injections market segmented by distribution channel will arise in the chemists segment, which will gain $1.5 billion of global annual sales by 2028. The top opportunities in the self-injections market segmented by route of administration will arise in the skin segment, which will gain $2.6 billion of global annual sales by 2028. The top opportunities in the self-injections market segmented by dosage will arise in the single dose segment, which will gain $2.3 billion of global annual sales by 2028. The self-injections market size will gain the most in the USA at $1.2 billion.

Market-trend-based strategies for the self-injections market include introduction of single-dose pre-filled injector for appropriate administration, focus on enhancing user experience by combining self-injection devices with an app, strategic partnerships and collaborations among market players and expansion of manufacturing facilities to broaden portfolio.

Player-adopted strategies in the self-injections market include focus on strengthening business operations through the launch of new products, enhancing operational capabilities through new product developments and product approvals and expanding business capabilities through strategic partnerships.

To take advantage of the opportunities, the analyst recommends self-injections companies to focus on single dose pre-filled delivery devices, focus on integrated self-injection solutions, focus on manufacturing expansion for portfolio growth, focus on formulations segment, focus on multi dose segment, focus on skin segment, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for distribution expansion, focus on value-based pricing strategies, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, focus on targeting end-users in hormonal disorders segment and focus on targeting hospital pharmacies.